UnknownNot Applicable

Diagnosis of MGRS in Patients With Paraproteinemias: Clinical, Anatomopathological and Pathophysiological Study

Argentina15 participantsStarted 2019-02-23

Plain-language summary

This is the first prospective study which evaluate patients with small B-cell clones to diagnose monoclonal gammopathy of renal significance (MGRS) and characterize it clinically, anatomopathologically and pathophysiologically taking int account a geriatric approach.

Who can participate

Age range18 Years – 89 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Paraproteinemias Exclusion Criteria: * Multiple Myeloma * Waldenstrom Macroglobulinemia * Chronic Lymphocytic Leukemia * Malignant Lymphoma * Monoclonal gammopathy of unknown significance (MGUS) secondary to Infections * MGUS secondary to Autoimmune Diseases * Uncompleted hematological evaluation * Renal tumor except for cysts Bosniak type I/II * Other malignant neoplasia * Unresolved obstructive uropathy * Patients with only one kidney except for renal transplant * Co-morbidities which would limit the ability to receive aggressive therapeutic intervention * Fragile old people * Pregnancy * Prison * Impatient in psychiatric institutions.

What they're measuring

Renal histopathology compatible with MGRS

Timeframe: through study completion, an average of 1 year

Trial details

NCT IDNCT03629561

SponsorAcademia Nacional de Medicina

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-11

Contact for this trial

Mariana Ciocchini, Nephrologist

+54 9 11 6172 2738 marianaciocchini@pm.me

View on ClinicalTrials.gov More Monoclonal Gammopathy of Renal Significance trials